Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40656 | 0.85 | CA2 (0.77) | CA2TDP1CA1CA12CA4 | |
| SCHEMBL6034023 | 0.84 | CA2 (0.50) | CA2TDP1CA1KDM4EALDH1A1 | |
| SCHEMBL6057959 | 0.82 | CA2 (0.72) | CA2TDP1CA1CA12CA4 | |
| SCHEMBL2212372 | 0.78 | CA2 (0.59) | CA2TDP1CA1CA12CA4 | |
| SCHEMBL22408786 | 0.78 | CA2 (0.59) | CA2TDP1CA1CA12CA4 | |
| SCHEMBL2643271 | 0.78 | CA2 (0.59) | CA2TDP1CA1CA12CA4 | |
| SCHEMBL12235091 | 0.78 | CA2 (0.59) | CA2TDP1CA1CA12CA4 | |
| SCHEMBL40703 | 0.77 | CA2 (0.65) | CA2TDP1CA1CA12CA4 | |
| SCHEMBL7719756 | 0.77 | CA2 (0.65) | CA2TDP1CA1CA12CA4 | |
| SCHEMBL2642543 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10876252-B2 | Process for dyeing and foaming thermoplastic polyurethane | HUNTSMAN INTERNATIONAL LLC (US) | 2020-12-29 | — | — | US | claimed |
| US-20200063338-A1 | PROCESS FOR DYEING AND FOAMING THERMOPLASTIC POLYURETHANE | HUNTSMAN INTERNATIONAL LLC | 2020-02-27 | — | — | US | claimed |
| EP-3541988-A1 | PROCESS FOR DYEING AND FOAMING THERMOPLASTIC POLYURETHANE | Huntsman International LLC (US) | 2019-09-25 | — | — | EP | claimed |
| EP-3141552-B1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM IND CO LTD (KR) | 2019-04-17 | — | — | EP | claimed |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2018-10-30 | — | — | US | claimed |
| WO-2018091446-A1 | PROCESS FOR DYEING AND FOAMING THERMOPLASTIC POLYURETHANE | HUNTSMAN INTERNATIONAL LLC (US) | 2018-05-24 | — | — | WO | claimed |
| EP-3141552-A1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2017-03-15 | — | — | EP | claimed |
| EP-2528920-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2012-12-05 | — | — | EP | claimed |
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-29 | — | — | US | claimed |
| EP-1980593-B1 | Colourant compounds for phase change inks | XEROX CORP (US) | 2012-08-15 | — | — | EP | claimed |
| WO-2011093672-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM. CO., LTD. (KR) | 2011-08-04 | — | — | WO | claimed |
| US-7749315-B2 | Contaaining polymeric dye or dimer thereof | XEROX CORPORATION (US) | 2010-07-06 | — | — | US | claimed |
| US-7381831-B1 | Colorant compounds | XEROX CORPORATION (US) | 2008-06-03 | — | — | US | claimed |
| US-10876252-B2 | Process for dyeing and foaming thermoplastic polyurethane | HUNTSMAN INTERNATIONAL LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200063338-A1 | PROCESS FOR DYEING AND FOAMING THERMOPLASTIC POLYURETHANE | HUNTSMAN INTERNATIONAL LLC | 2020-02-27 | — | — | US | disclosed |
| EP-3541988-A1 | PROCESS FOR DYEING AND FOAMING THERMOPLASTIC POLYURETHANE | Huntsman International LLC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1671962-A1 | NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-21 | — | — | EP | disclosed |
| EP-1598349-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-23 | — | — | EP | disclosed |
| EP-1087935-B1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INT LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | CDK2, SBK3, CDK2AP1 | CA2 1561/4885TDP1 2250/4885CA1 3727/4885 |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | CDK2, SBK3, CDK2AP1 | CA2 1561/4885TDP1 2250/4885CA1 3727/4885 |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | GCKR, GCK, HK2 | CA2 81/4885TDP1 4580/4885CA1 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.